Trial · NCT03605758
Treatment of Strongyloides Infection
NCT03605758, Phase 3, Terminated, Albert Einstein College of Medicine; results first posted 2023-11-30
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Treatment of Strongyloides Infection. Trials, record NCT03605758. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03605758
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Treatment of Strongyloides Infection
- NCT number
- NCT03605758
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 51 participants, actual
- Lead sponsor
- Albert Einstein College of Medicine
- Conditions
- Strongyloides Stercoralis Infection, Strongyloidiasis
- Interventions
- Ivermectin
- First posted
- 2018-07-30
- Last updated
- 2023-11-30
- Results first posted
- 2023-11-30
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Level of Strongyloides Serology as Measured by ELISA at 3-4 Months Post-treatment | 3-4 months post treatment | The level of Strongyloides serology as measured by Enzyme-linked immunosorbent assay (ELISA) indicates presence of infection. \>0.3 OD (optical density) means positive for infection while \<0.29 OD means negative (no infection). |
| Primary | Level of Strongyloides Serology as Measured by ELISA at 6-8 Months Post-treatment | 6-8 months post treatment | The level of Strongyloides serology as measured by Enzyme-linked immunosorbent assay (ELISA) indicates presence of infection. \>0.3 OD (optical density) means positive for infection while \<0.29 OD means negative (no infection). |
| Primary | Level of Strongyloides Serology as Measured by ELISA at 9-12 Months Post-treatment | 9-12 months post treatment | The level of Strongyloides serology as measured by Enzyme-linked immunosorbent assay (ELISA) indicates presence of infection. \>0.3 OD (optical density) means positive for infection while \<0.29 OD means negative (no infection). |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Level of Strongyloides Serology as Measured by ELISA at 3-4 Months Post-treatment | 3-4 months post treatment | Serology samples at 3-4 months post treatment were not collected/processed and therefore serology data is not available. | ||
| PRIMARY | Level of Strongyloides Serology as Measured by ELISA at 6-8 Months Post-treatment | 6-8 months post treatment | Serology samples at 6-8 months post treatment were not collected/processed and therefore serology data is not available. | ||
| PRIMARY | Level of Strongyloides Serology as Measured by ELISA at 9-12 Months Post-treatment | 9-12 months post treatment | Serology samples at 9-12 months post treatment were not collected/processed and therefore serology data is not available. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Ivermectin Administered on Two Consecutive Days (Days 1 and 2) | 22 | |
| Overall Study | STARTED | Ivermectin Administered Two Weeks Apart (Days 1 and 14) | 26 | |
| Overall Study | COMPLETED | Ivermectin Administered on Two Consecutive Days (Days 1 and 2) | 0 | |
| Overall Study | COMPLETED | Ivermectin Administered Two Weeks Apart (Days 1 and 14) | 2 | |
| Overall Study | NOT COMPLETED | Ivermectin Administered on Two Consecutive Days (Days 1 and 2) | 22 | |
| Overall Study | NOT COMPLETED | Ivermectin Administered Two Weeks Apart (Days 1 and 14) | 24 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Ivermectin Administered on Two Consecutive Days (Days 1 and 2) | 0 | 22 |
| Total, all-cause mortality | Ivermectin Administered Two Weeks Apart (Days 1 and 14) | 0 | 26 |
| Total, all-cause mortality | Participants Assessed for Events Prior to Randomization | 1 | 51 |
| Total, other adverse events | Ivermectin Administered on Two Consecutive Days (Days 1 and 2) | 0 | 22 |
| Total, other adverse events | Ivermectin Administered Two Weeks Apart (Days 1 and 14) | 0 | 26 |
| Total, other adverse events | Participants Assessed for Events Prior to Randomization | 0 | 0 |
| Total, serious adverse events | Ivermectin Administered on Two Consecutive Days (Days 1 and 2) | 0 | 22 |
| Total, serious adverse events | Ivermectin Administered Two Weeks Apart (Days 1 and 14) | 0 | 26 |
| Total, serious adverse events | Participants Assessed for Events Prior to Randomization | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03605758
GET https://conductscience.org/api/trials/v1/NCT03605758/registered